Proud to contribute to the Phase III Krascendo 1 study, presented at #ESMO2026 and published in @NEJM. Co-author @BoWangMD1 called the findings “potentially practice-changing” for

Sarah Cannon Docs· @SarahCannonDocs · X·2026-10-25 23:15· 1 day agoScore70

Body · original

Proud to contribute to the Phase III Krascendo 1 study, presented at #ESMO2026 and published in @NEJM. Co-author @BoWangMD1 called the findings “potentially practice-changing” for patients with KRAS G12C-mutated lung cancer. https://www.scri.com/news/sarah-cannon-research-institute-showcases-85-oncology-research-presentations--at-esmo-2026-highlighting-advances-across-multiple-tumor-types2/

7 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

2551TIPNCT07541170 NCT07541170 NCT07541170matched by NSCLC, early stage

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

Source: Sarah Cannon Docs · x.com